Arshad M. Khanani, MD, MA; and Nancy M. Holekamp, MD, review how the treatment of neovascular AMD has changed over the years, from thermal laser to different dosing strategies of anti-VEGFs, plus real-world experience with these regimens. They also discuss novel investigational therapies and how they are expected to have a positive impact on the lives of retina patients.
This continuing medical education activity is supported by an educational grant from Genentech.
Upon completion of this activity, the participant should be able to:
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Arshad M. Khanani, MD, MA
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno School of Medicine
Nancy M. Holekamp, MD
Pepose Vision Institute
Professor of Clinical Ophthalmology
Washington University School of Medicine
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Arshad M. Khanani, MD, MA, and or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Adverum Biotechnologies, Allegro, Allergan, Bausch + Lomb, Eyepoint, Graybug, Gemini, Genentech, Gyroscope, Kodiak Sciences, Novartis, Opthea, Oxurion, Polyphotonix, Recens Medical, and Regenxbio. Grant/Research Support: Adverum Biotechnologies, Allergan, Gemini, Genentech, Graybug, Gyroscope, IVERIC Bio, Kodiak Sciences, Novartis, Opthea, Oxurion, Recens Medical, and Regenxbio. Speaker’s Bureau: Allergan, and Novartis.
Nancy Holekamp, MD, and or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Gemini, Genentech, Lineage Cell Therapeutics, Novartis, Regeneron Pharmaceuticals, and ViewPoint Therapeutics. Grant/Research Support: Gemini, Genentech, Gyroscope, and Notal Vision. Speaker’s Bureau: Allergan, Genentech, Novartis, Regeneron Pharmaceuticals, and Spark Therapeutics. Stock/Shareholder: Katalyst.
The staff and planners at Evolve Medical Education have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.